Billy Schumpert
Family Medicine · Cleveland, OKNPI 1306885934
Payments from drug & device makers
Across 199 payments — averaging $14.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$634
- Lilly USA, LLC$398
- GSK$382
- AstraZeneca$372
- Amgen$155
- Merck$135
- plus $797 from 19 others
What the payments were for
- Food & beverage$2,871100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 61 | $634 |
| Lilly USA, LLC | 28 | $398 |
| GSK | 25 | $382 |
| AstraZeneca | 20 | $372 |
| Amgen | 11 | $155 |
| Merck | 9 | $135 |
| Astellas Pharma US Inc | 5 | $122 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $97 |
| Novo Nordisk | 6 | $88 |
| Novartis | 4 | $69 |
| Pfizer | 4 | $61 |
| Boehringer Ingelheim | 3 | $52 |
| Otsuka America Pharmaceutical, Inc. | 3 | $51 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $46 |
| Sumitomo Pharma America, Inc. | 2 | $35 |
| Exact Sciences | 1 | $22 |
| Lundbeck LLC | 1 | $22 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $17 |
| Biogen | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Abbott | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $13 |
How this compares
$2,871 in reported general payments places this provider in the 75th percentile of 1,730 family medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 114 | $84,658 |
| EliquisApixaban | 76 | $63,035 |
| JardianceEmpagliflozin | 55 | $57,058 |
| TrulicityDulaglutide | 29 | $45,569 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 12 | $42,148 |
| OzempicSemaglutide | 39 | $40,782 |
| JanuviaSitagliptin Phosphate | 23 | $22,381 |
| XareltoRivaroxaban | 17 | $20,327 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $4,886 |
| DuleraMometasone/Formoterol | 13 | $4,301 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $3,761 |
| Gabapentin | 226 | $3,630 |
| Ventolin HfaAlbuterol Sulfate | 39 | $3,072 |
| Atorvastatin Calcium | 293 | $2,707 |
| SynthroidLevothyroxine Sodium | 25 | $2,640 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Incruse Ellipta | $382 | $88,419125 claims |
| PfizerEliquis | $61 | $63,03576 claims |
| Boehringer IngelheimJardiance | $52 | $57,05855 claims |
| Lilly USA, LLCTrulicity | $398 | $45,56929 claims |
| Novo NordiskOzempic | $88 | $40,78239 claims |
| MerckJanuvia, Dulera | $135 | $26,68136 claims |
| Johnson & JohnsonXarelto | $17 | $20,32717 claims |
| AbbVieSynthroid | $634 | $2,64025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Cleveland
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.